{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:21:32Z","timestamp":1792869692789,"version":"4.5.0"},"reference-count":145,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.diabet.2025.101612","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T16:42:45Z","timestamp":1736872965000},"page":"101612","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9743-4371","authenticated-orcid":false,"given":"Andr\u00e9 J.","family":"Scheen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101612_bib0001","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev-nutr-071715-050909","article-title":"The neurobiology of \"food addiction\" and its implications for obesity treatment and policy","volume":"36","author":"Carter","year":"2016","journal-title":"Annu Rev Nutr"},{"key":"10.1016\/j.diabet.2025.101612_bib0002","series-title":"Food & addiction: a comprehensive handbook","author":"Gearhardt","year":"2024"},{"key":"10.1016\/j.diabet.2025.101612_bib0003","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/10550887.2021.1939630","article-title":"Food addiction among morbidly obese patients: prevalence and links with obesity complications","volume":"40","author":"Som","year":"2022","journal-title":"J Addict Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0004","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41386-018-0203-9","article-title":"Food addiction: a valid concept?","volume":"43","author":"Fletcher","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.diabet.2025.101612_bib0005","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1007\/s11695-024-07107-6","article-title":"Bariatric-metabolic surgery is the most effective intervention in reducing food addiction symptoms: a systematic review and meta-analysis","volume":"34","author":"Reche-Garcia","year":"2024","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0006","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1002\/erv.2399","article-title":"Alcohol and other addictive disorders following bariatric surgery: prevalence, risk factors and possible etiologies","volume":"23","author":"Steffen","year":"2015","journal-title":"Eur Eat Disord Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0007","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/obr.12542","article-title":"Obesity and addiction: can a complication of surgery help us understand the connection?","volume":"18","author":"Ivezaj","year":"2017","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0008","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41574-018-0006-4","article-title":"Psychological issues and alcohol misuse following bariatric surgery","volume":"14","author":"Hardman","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.diabet.2025.101612_bib0009","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3389\/fnins.2013.00181","article-title":"The central GLP-1: implications for food and drug reward","volume":"7","author":"Skibicka","year":"2013","journal-title":"Front Neurosci"},{"key":"10.1016\/j.diabet.2025.101612_bib0010","series-title":"Food & addiction: a comprehensive handbook","first-page":"424","article-title":"Pharmacotherapy for obesity that targets addictive mechanisms","author":"Aras","year":"2024"},{"key":"10.1016\/j.diabet.2025.101612_bib0011","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1467-789X.2012.01031.x","article-title":"Obesity and addiction: neurobiological overlaps","volume":"14","author":"Volkow","year":"2013","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0012","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2023.1240748","article-title":"Linking drug and food addiction: an overview of the shared neural circuits and behavioral phenotype","volume":"17","author":"Passeri","year":"2023","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.diabet.2025.101612_bib0013","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.physbeh.2019.03.029","article-title":"The effect of glucagon-like peptide-1 (GLP-1) receptor agonists on substance use disorder (SUD)-related behavioural effects of drugs and alcohol: a systematic review","volume":"206","author":"Brunchmann","year":"2019","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0014","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bph.15677","article-title":"The role of glucagon-like peptide 1 (GLP-1) in addictive disorders","volume":"179","author":"Klausen","year":"2022","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.diabet.2025.101612_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107312","article-title":"IUPHAR review - Glucagon-like peptide-1 (GLP-1) and substance use disorders: an emerging pharmacotherapeutic target","volume":"207","author":"Bruns Vi","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2024.112424","article-title":"Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials","volume":"264","author":"Martinelli","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.diabet.2025.101612_bib0017","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.2024.1017","article-title":"Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions?","volume":"331","author":"Rubin","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101612_bib0018","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.diabet.2025.101612_bib0019","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.suc.2020.12.005","article-title":"Addiction transfer and other behavioral changes following bariatric surgery","volume":"101","author":"Koball","year":"2021","journal-title":"Surg Clin N Am"},{"key":"10.1016\/j.diabet.2025.101612_bib0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/2013.jamasurg.265","article-title":"Substance use following bariatric weight loss surgery","volume":"148","author":"Conason","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0021","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1111\/obr.12600","article-title":"Food addiction and bariatric surgery: a systematic review of the literature","volume":"18","author":"Ivezaj","year":"2017","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0022","doi-asserted-by":"crossref","first-page":"e13529","DOI":"10.1111\/obr.13529","article-title":"Prevalence of food addiction among patients undergoing metabolic\/bariatric surgery: a systematic review and meta-analysis","volume":"24","author":"Praxedes","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0023","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1007\/s11695-016-2189-x","article-title":"Food addiction in bariatric surgery candidates: prevalence and risk factors","volume":"26","author":"Brunault","year":"2016","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0024","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/erv.2629","article-title":"Food addiction and other addictive behaviours in bariatric surgery candidates","volume":"26","author":"M\u00fcller","year":"2018","journal-title":"Eur Eat Disord Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0025","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1111\/adb.12436","article-title":"The gut in the brain: the effects of bariatric surgery on alcohol consumption","volume":"22","author":"Blackburn","year":"2017","journal-title":"Addict Biol"},{"key":"10.1016\/j.diabet.2025.101612_bib0026","doi-asserted-by":"crossref","first-page":"e738","DOI":"10.1002\/osp4.738","article-title":"Food and alcohol disturbance among people who have undergone bariatric surgery","volume":"10","author":"White","year":"2024","journal-title":"Obes Sci Pract"},{"key":"10.1016\/j.diabet.2025.101612_bib0027","doi-asserted-by":"crossref","first-page":"e12551","DOI":"10.1111\/cob.12551","article-title":"Patients' perceptions of the mechanisms underlying alcohol use problems after bariatric surgery: a qualitative systematic review","volume":"13","author":"Er","year":"2023","journal-title":"Clin Obes"},{"key":"10.1016\/j.diabet.2025.101612_bib0028","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.soard.2007.03.004","article-title":"Alcohol misuse after bariatric surgery: epiphenomenon or \"Oprah\" phenomenon?","volume":"3","author":"Sogg","year":"2007","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0029","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.soard.2008.01.004","article-title":"Alcohol abuse and dependence before and after bariatric surgery: a review of the literature and report of a new data set","volume":"4","author":"Ertelt","year":"2008","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0030","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.soard.2012.01.016","article-title":"Alcohol and bariatric surgery: review and suggested recommendations for assessment and management","volume":"8","author":"Heinberg","year":"2012","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0031","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1111\/acer.12805","article-title":"Alcohol and drug use among postoperative bariatric patients: a systematic review of the emerging research and its implications","volume":"39","author":"Spadola","year":"2015","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0032","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.2012.6147","article-title":"Prevalence of alcohol use disorders before and after bariatric surgery","volume":"307","author":"King","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.diabet.2025.101612_bib0033","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1002\/oby.20397","article-title":"Alcohol consumption and alcohol problems after bariatric surgery in the Swedish obese subjects study","volume":"21","author":"Svensson","year":"2013","journal-title":"Obesity"},{"key":"10.1016\/j.diabet.2025.101612_bib0034","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamasurg.2013.700","article-title":"Increased admission for alcohol dependence after gastric bypass surgery compared with restrictive bariatric surgery","volume":"148","author":"Ostlund","year":"2013","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0035","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.soard.2017.03.021","article-title":"Alcohol and other substance use after bariatric surgery: prospective evidence from a U.S. multicenter cohort study","volume":"13","author":"King","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0036","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1007\/s00464-018-6545-x","article-title":"New onset alcohol use disorder following bariatric surgery","volume":"33","author":"Ibrahim","year":"2019","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0037","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.soard.2019.12.011","article-title":"Diagnoses related to abuse of alcohol and addictive substances after gastric bypass and sleeve gastrectomy: a nation-wide registry study from Norway","volume":"16","author":"Strommen","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0038","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.28117","article-title":"Association of bariatric surgical procedures with changes in unhealthy alcohol use among US Veterans","volume":"3","author":"Maciejewski","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2025.101612_bib0039","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/liv.14805","article-title":"Bariatric surgery and the risk of alcohol-related cirrhosis and alcohol misuse","volume":"41","author":"Mellinger","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.diabet.2025.101612_bib0040","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1093\/ije\/dyaa147","article-title":"Bariatric surgery and risk of alcohol use disorder: a register-based cohort study","volume":"49","author":"Bramming","year":"2021","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.diabet.2025.101612_bib0041","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1007\/s11695-023-06490-w","article-title":"Bariatric surgery is associated with alcohol-related liver disease and psychiatric disorders associated with AUD","volume":"33","author":"Alvarado-Tapias","year":"2023","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0042","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jamasurg.2022.6410","article-title":"Association between bariatric surgery and alcohol use-related hospitalization and all-cause mortality in a Veterans Affairs cohort","volume":"158","author":"Mahmud","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0043","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/08897077.2016.1262305","article-title":"Alcohol use patterns and alcohol use disorders among young adult, ethnically diverse bariatric surgery patients","volume":"38","author":"Spadola","year":"2017","journal-title":"Subst Abuse"},{"key":"10.1016\/j.diabet.2025.101612_bib0044","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1038\/s41366-024-01606-3","article-title":"Alcohol use disorders after bariatric surgery: a study using linked health claims and survey data","volume":"48","author":"Riedel","year":"2024","journal-title":"Int J Obes"},{"key":"10.1016\/j.diabet.2025.101612_bib0045","doi-asserted-by":"crossref","first-page":"e519","DOI":"10.1097\/SLA.0000000000005759","article-title":"A prospective cohort of alcohol use and alcohol-related problems before and after metabolic and bariatric surgery in adolescents","volume":"278","author":"White","year":"2023","journal-title":"Ann Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0046","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s40519-019-00663-2","article-title":"Binge eating disorder is not predictive of alcohol abuse disorders in long-term follow-up period after Roux-en-Y gastric bypass surgery","volume":"25","author":"Freire","year":"2020","journal-title":"Eat Weight Disord"},{"key":"10.1016\/j.diabet.2025.101612_bib0047","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s11695-021-05847-3","article-title":"High-risk alcohol use and disordered eating behavior before and 1 year after sleeve gastrectomy","volume":"32","author":"Wong","year":"2022","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0048","doi-asserted-by":"crossref","first-page":"148","DOI":"10.21037\/atm.2018.03.16","article-title":"Alcohol use disorders before and after bariatric surgery: a systematic review and meta-analysis","volume":"6","author":"Azam","year":"2018","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0049","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/erv.2857","article-title":"No addiction transfer from preoperative food addiction to other addictive behaviors during the first year after bariatric surgery","volume":"29","author":"Dickhut","year":"2021","journal-title":"Eur Eat Disord Rev"},{"key":"10.1016\/j.diabet.2025.101612_bib0050","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1080\/09540261.2023.2223317","article-title":"Bariatric surgery and its influence on alcohol consumption: differences before and after surgery - A systematic review and meta-analysis","volume":"35","author":"Capelo Vides","year":"2023","journal-title":"Int Rev Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0051","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.soard.2015.10.085","article-title":"ASMBS position statement on alcohol use before and after bariatric surgery","volume":"12","author":"Parikh","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0052","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1007\/s13679-024-00577-w","article-title":"Alcohol misuse post metabolic and bariatric surgery: a systematic review of longer-term studies with focus on new onset alcohol use disorder and differences between surgery types","volume":"13","author":"Kenkre","year":"2024","journal-title":"Curr Obes Rep"},{"key":"10.1016\/j.diabet.2025.101612_bib0053","doi-asserted-by":"crossref","first-page":"e13441","DOI":"10.1111\/adb.13441","article-title":"The glucagon-like peptide-1 and other endocrine responses to alcohol ingestion in women with versus without metabolic surgery","volume":"29","author":"Molina-Castro","year":"2024","journal-title":"Addict Biol"},{"key":"10.1016\/j.diabet.2025.101612_bib0054","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.soard.2020.01.014","article-title":"Alcohol sensitivity in women after undergoing bariatric surgery: a cross-sectional study","volume":"16","author":"Acevedo","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0055","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.soard.2017.11.010","article-title":"Sleeve gastrectomy surgery: when 2 alcoholic drinks are converted to 4","volume":"14","author":"Acevedo","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0056","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.soard.2021.08.011","article-title":"The rewarding effects of alcohol after bariatric surgery: do they change and are they associated with pharmacokinetic changes?","volume":"18","author":"Engel","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0057","doi-asserted-by":"crossref","first-page":"agae007","DOI":"10.1093\/alcalc\/agae007","article-title":"Bariatric surgery patients in AUD treatment in Norway-an exploratory cross-sectional study","volume":"59","author":"Bramness","year":"2024","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.diabet.2025.101612_bib0058","doi-asserted-by":"crossref","first-page":"e0139","DOI":"10.1097\/CLD.0000000000000139","article-title":"The impact of alcohol on patients after bariatric surgery","volume":"23","author":"Grover","year":"2024","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0059","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.soard.2019.04.007","article-title":"Drug- and alcohol-related mortality risk after bariatric surgery: evidence from a 7-year prospective multicenter cohort study","volume":"15","author":"White","year":"2019","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0060","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jamasurg.2022.6526","article-title":"Alcohol use following bariatric surgery-A cause for concern and call to action","volume":"158","author":"Gould","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0061","doi-asserted-by":"crossref","first-page":"5936","DOI":"10.1007\/s00464-021-08654-0","article-title":"Impact of smoking on weight loss outcomes after bariatric surgery: a literature review","volume":"35","author":"Mohan","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0062","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1007\/s00464-020-07827-7","article-title":"Effects of smoking on bariatric surgery postoperative weight loss and patient satisfaction","volume":"35","author":"Samaan","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0063","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.soard.2018.05.004","article-title":"Cigarette smoking and its impact on weight loss after bariatric surgery: a single center, retrospective study","volume":"14","author":"Kowalewski","year":"2018","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0064","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/j.1445-2197.1990.tb07469.x","article-title":"Psychosocial and physical activity changes after gastric restrictive procedures for morbid obesity","volume":"60","author":"Hawke","year":"1990","journal-title":"Aust N Z J Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0065","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.eatbeh.2013.08.008","article-title":"Smoking and alcohol use in gastric bypass patients","volume":"14","author":"Lent","year":"2013","journal-title":"Eat Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0066","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12971-015-0045-8","article-title":"Smoking habit in severe obese after bariatric procedures","volume":"13","author":"Maniscalco","year":"2015","journal-title":"Tob Induc Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0067","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpsychires.2016.01.009","article-title":"Substance use after bariatric surgery: a review","volume":"76","author":"Li","year":"2016","journal-title":"J Psychiatr Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0068","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/SLA.0000000000003828","article-title":"Changes in smoking behavior before and after gastric bypass: a 7-year study","volume":"275","author":"King","year":"2022","journal-title":"Ann Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0069","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11695-020-04907-4","article-title":"Smoking behaviour and beliefs about smoking cessation after bariatric surgery","volume":"31","author":"Wolvers","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0070","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00464-020-07669-3","article-title":"Smoking in bariatric surgery: a systematic review","volume":"35","author":"Chow","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0071","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s11605-019-04488-3","article-title":"Post-operative complications and readmissions associated with smoking following bariatric surgery","volume":"24","author":"Yuce","year":"2020","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0072","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11920-020-01218-4","article-title":"Marijuana and bariatric surgery","volume":"23","author":"Diggins","year":"2021","journal-title":"Curr Psychiatry Rep"},{"key":"10.1016\/j.diabet.2025.101612_bib0073","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/s00464-020-07497-5","article-title":"Marijuana use does not affect the outcomes of bariatric surgery","volume":"35","author":"Shockcor","year":"2021","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0074","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.soard.2015.06.007","article-title":"Postoperative marijuana use and disordered eating among bariatric surgery patients","volume":"12","author":"Vidot","year":"2016","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0075","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.soard.2023.09.009","article-title":"Cannabis use following bariatric surgery is associated with anxiety and maladaptive eating","volume":"20","author":"Miller-Matero","year":"2024","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0076","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.soard.2020.12.004","article-title":"Cannabis use and bariatric surgery psychology practice: survey and insights","volume":"17","author":"Goetze","year":"2021","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0077","doi-asserted-by":"crossref","DOI":"10.7812\/TPP\/18-002","article-title":"Marijuana's influence on pain scores, initial weight loss, and other bariatric surgical outcomes","volume":"22","author":"Bauer","year":"2018","journal-title":"Perm J"},{"key":"10.1016\/j.diabet.2025.101612_bib0078","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00464-022-09481-7","article-title":"Opioid prescribing practices following bariatric surgery: a systematic review and pooled proportion meta-analysis","volume":"37","author":"Lin","year":"2023","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0079","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00464-022-09291-x","article-title":"New persistent opioid use after bariatric surgery: a systematic review and pooled proportion meta-analysis","volume":"37","author":"Nasser","year":"2023","journal-title":"Surg Endosc"},{"key":"10.1016\/j.diabet.2025.101612_bib0080","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.3390\/jcm12134296","article-title":"Opioid analgesics after bariatric surgery: a scoping review to evaluate physiological risk factors for opioid-related harm","volume":"12","author":"Wuyts","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0081","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.soard.2020.04.037","article-title":"Long-term opioid use after bariatric surgery","volume":"16","author":"Maciejewski","year":"2020","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0082","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.soard.2021.08.010","article-title":"Opioid consumption in patients undergoing Roux-en-Y bariatric surgery compared with population controls with and without obesity","volume":"18","author":"Svensson","year":"2022","journal-title":"Surg Obes Relat Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0083","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/oby.23800","article-title":"Non-alcohol substance use disorder after bariatric surgery in the prospective, controlled Swedish Obese Subjects study","volume":"31","author":"Svensson","year":"2023","journal-title":"Obesity"},{"key":"10.1016\/j.diabet.2025.101612_bib0084","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2023.1206938","article-title":"Development of gambling disorder after bariatric surgery: a call for research","volume":"11","author":"Abdul Rahim","year":"2023","journal-title":"Front Public Health"},{"key":"10.1016\/j.diabet.2025.101612_bib0085","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1063033","article-title":"The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies","volume":"14","author":"Jerlhag","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2025.101612_bib0086","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-23-0405","article-title":"The emerging role of glucagon-like peptide 1 in binge eating","volume":"262","author":"Balantekin","year":"2024","journal-title":"J Endocrinol"},{"key":"10.1016\/j.diabet.2025.101612_bib0087","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ADM.0000000000001347","article-title":"The efficacy of GLP-1 agonists in treating substance use disorder in patients: a scoping review","volume":"18","author":"Shen","year":"2024","journal-title":"J Addict Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0088","first-page":"5","article-title":"Social media as pharmacovigilance: the potential for patient reports to inform clinical research on glucagon-like peptide 1 (GLP-1) receptor agonists for substance use disorders","volume":"85","author":"Bremmer","year":"2024","journal-title":"J Stud Alcohol Drugs"},{"key":"10.1016\/j.diabet.2025.101612_bib0089","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0090","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2020","journal-title":"Front Behav Neurosci"},{"key":"10.1016\/j.diabet.2025.101612_bib0091","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabet.2025.101612_bib0092","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2022.113967","article-title":"Short term effects of semaglutide on emotional eating and other abnormal eating patterns among subjects living with obesity","volume":"257","author":"Nicolau","year":"2022","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0093","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/10550887.2024.2315365","article-title":"Short-term effects of semaglutide among patients with obesity with and without food addiction: an observational study","volume":"42","author":"Nicolau","year":"2024","journal-title":"J Addict Dis"},{"key":"10.1016\/j.diabet.2025.101612_bib0094","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40263-014-0178-y","article-title":"Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy","volume":"28","author":"Engel","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.diabet.2025.101612_bib0095","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.cobeha.2016.02.005","article-title":"GLP-1 influences food and drug reward","volume":"9","author":"Hayes","year":"2016","journal-title":"Curr Opin Behav Sci"},{"key":"10.1016\/j.diabet.2025.101612_bib0096","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.neuropharm.2018.01.013","article-title":"GLP-1 signaling and alcohol-mediated behaviors; preclinical and clinical evidence","volume":"136","author":"Jerlhag","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.diabet.2025.101612_bib0097","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146562","article-title":"Alcohol-mediated behaviours and the gut-brain axis; with focus on glucagon-like peptide-1","volume":"1727","author":"Jerlhag","year":"2020","journal-title":"Brain Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0098","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabet.2025.101612_bib0099","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00213-018-5089-z","article-title":"Effects of glucagon-like peptide 1 analogs on alcohol intake in alcohol-preferring vervet monkeys","volume":"236","author":"Thomsen","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.diabet.2025.101612_bib0100","doi-asserted-by":"crossref","first-page":"e583","DOI":"10.1038\/tp.2015.68","article-title":"The glucagon-like peptide-1 receptor as a potential treatment target in alcohol use disorder: evidence from human genetic association studies and a mouse model of alcohol dependence","volume":"5","author":"Suchankova","year":"2015","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0101","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.908948","article-title":"Genetic variability of incretin receptors and alcohol dependence: a pilot study","volume":"15","author":"Tsermpini","year":"2022","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.diabet.2025.101612_bib0102","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.159863","article-title":"Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial","volume":"7","author":"Klausen","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabet.2025.101612_bib0103","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170419","article-title":"Effects of dulaglutide on alcohol consumption during smoking cessation","volume":"8","author":"Probst","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.diabet.2025.101612_bib0104","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","article-title":"Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study","volume":"131","author":"Wium-Andersen","year":"2022","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.diabet.2025.101612_bib0105","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1038\/s41467-024-48780-6","article-title":"Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.diabet.2025.101612_bib0106","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/add.16679","article-title":"The association between glucose-dependent insulinotropic polypeptide and\/or glucagon-like peptide-1 receptor agonist prescriptions and substance-related outcomes in patients with opioid and alcohol use disorders: a real-world data analysis","volume":"120","author":"Qeadan","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.diabet.2025.101612_bib0107","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/jamapsychiatry.2024.3599","article-title":"Repurposing semaglutide and liraglutide for alcohol use disorder","volume":"82","author":"Lahteenvuo","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0108","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.47644","article-title":"Alcohol use and antiobesity medication treatment","volume":"7","author":"Miller-Matero","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2025.101612_bib0109","doi-asserted-by":"crossref","first-page":"20998","DOI":"10.1038\/s41598-023-48267-2","article-title":"Semaglutide and tirzepatide reduce alcohol consumption in individuals with obesity","volume":"13","author":"Quddos","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.diabet.2025.101612_bib0110","doi-asserted-by":"crossref","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0111","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3390\/brainsci14060617","article-title":"Exploring the potential impact of GLP-1 receptor agonists on substance use, compulsive behavior, and libido: insights from social media using a mixed-methods approach","volume":"14","author":"Arillotta","year":"2024","journal-title":"Brain Sci"},{"key":"10.1016\/j.diabet.2025.101612_bib0112","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1016\/j.eclinm.2024.102920","article-title":"Association between glucagon-like peptide-1 receptor agonists use and change in alcohol consumption: a systematic review","volume":"78","author":"Subhani","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101612_bib0113","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1038\/s41380-024-02498-5","article-title":"Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study","volume":"29","author":"Wang","year":"2024","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0114","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12991-024-00527-9","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1RAs) as treatment for nicotine cessation in psychiatric populations: a systematic review","volume":"23","author":"Lee","year":"2024","journal-title":"Ann Gen Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112466","article-title":"GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity","volume":"42","author":"Falk","year":"2023","journal-title":"Cell Rep"},{"key":"10.1016\/j.diabet.2025.101612_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2024.114565","article-title":"Targeting GLP-1 receptors to reduce nicotine use disorder: preclinical and clinical evidence","volume":"281","author":"Herman","year":"2024","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0117","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ntr\/ntab066","article-title":"Exenatide adjunct to nicotine patch facilitates smoking cessation and may reduce post-cessation weight gain: a pilot randomized controlled trial","volume":"23","author":"Yammine","year":"2021","journal-title":"Nicotine Tob Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0118","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101865","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: a single-centre, randomized, double-blind, placebo-controlled, parallel group trial","volume":"57","author":"Lengsfeld","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101612_bib0119","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102429","article-title":"Effect of dulaglutide in promoting abstinence during smoking cessation: 12-month follow-up of a single-centre, randomised, double-blind, placebo-controlled, parallel group trial","volume":"68","author":"Luthi","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.diabet.2025.101612_bib0120","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","article-title":"Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data","volume":"177","author":"Wang","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0121","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17512433.2024.2418398","article-title":"Semaglutide and smoking cessation in individuals with type 2 diabetes mellitus: there is no smoke without fire!","volume":"17","author":"Popovic","year":"2024","journal-title":"Expert Rev Clin Pharmacol"},{"key":"10.1016\/j.diabet.2025.101612_bib0122","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.diabres.2019.01.033","article-title":"Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: an integrative review","volume":"149","author":"Yammine","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.diabet.2025.101612_bib0123","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13063-023-07164-9","article-title":"Glucagon-like peptide-1 analogues: a new way to quit smoking? (SKIP)-a structured summary of a study protocol for a randomized controlled study","volume":"24","author":"Lengsfeld","year":"2023","journal-title":"Trials"},{"key":"10.1016\/j.diabet.2025.101612_bib0124","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1038\/tp.2016.86","article-title":"Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels","volume":"6","author":"Reddy","year":"2016","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0125","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.physbeh.2019.03.026","article-title":"Central GLP-1 receptors: novel molecular targets for cocaine use disorder","volume":"206","author":"Hernandez","year":"2019","journal-title":"Physiol Behav"},{"key":"10.1016\/j.diabet.2025.101612_bib0126","doi-asserted-by":"crossref","unstructured":"Merkel R., Hernandez N., Weir V., Zhang Y., Rich M.T., Crist R.C., et al. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. bioRxiv 2024:Jun 24:2024.06.20.599574 (Preprint).","DOI":"10.1101\/2024.06.20.599574"},{"key":"10.1016\/j.diabet.2025.101612_bib0127","article-title":"Possible mechanisms underlying the effects of glucagon-like peptide-1 receptor agonist on cocaine use disorder","volume":"13","author":"Zhu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.diabet.2025.101612_bib0128","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41386-018-0035-7","article-title":"Can anti-obesity drugs be repurposed to treat cocaine addiction?","volume":"43","author":"Reiner","year":"2018","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.diabet.2025.101612_bib0129","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","article-title":"Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study","volume":"17","author":"Yammine","year":"2023","journal-title":"J Addict Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","article-title":"Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder","volume":"221","author":"Angarita","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.diabet.2025.101612_bib0131","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.35247","article-title":"Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder","volume":"7","author":"Wang","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.diabet.2025.101612_bib0132","unstructured":"Appenzeller T. Obesity drug cuts opiate craving. Grigson P. Obesity meets its match. Presentation at the annual meeting of the American Association for the Advancement of Science, Denver. February 17, 2024. Reported by https:\/\/www.science.org\/content\/article\/obesity-drug-cuts-opiate-craving#:\u223c:text=A%20small%20clinical%20trial%20has%20shown%20that%20blockbuster,2%20diabetes%2C%20may%20reduce%20cravings%20in%20opiat%20addiction."},{"key":"10.1016\/j.diabet.2025.101612_bib0133","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","article-title":"GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders","volume":"29","author":"Leggio","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.diabet.2025.101612_bib0134","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.psyneuen.2012.11.009","article-title":"The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents","volume":"38","author":"Egecioglu","year":"2013","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.diabet.2025.101612_bib0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000540743","article-title":"Gut hormones: possible mediators of addictive disorders?","author":"Nestor","year":"2024","journal-title":"Eur Addict Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0136","article-title":"Insight into the role of the gut-brain axis in alcohol-related responses: emphasis on GLP-1, amylin, and ghrelin","volume":"13","author":"Tufvesson-Alm","year":"2022","journal-title":"Front Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0137","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/nrn.2017.130","article-title":"The dopamine motive system: implications for drug and food addiction","volume":"18","author":"Volkow","year":"2017","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.diabet.2025.101612_bib0138","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/add.16626","article-title":"GLP-1R agonist medications for addiction treatment","volume":"120","author":"Volkow","year":"2025","journal-title":"Addiction"},{"key":"10.1016\/j.diabet.2025.101612_bib0139","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110303","article-title":"The therapeutic potential of GLP-1 analogues for stress-related eating and role of GLP-1 in stress, emotion and mood: a review","volume":"110","author":"Guerrero-Hreins","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.diabet.2025.101612_bib0140","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"10.1016\/j.diabet.2025.101612_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 receptor agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0142","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.neuroscience.2023.07.031","article-title":"Neuroimmune mechanisms of opioid use disorder and recovery: translatability to human studies, and future research directions","volume":"528","author":"Butelman","year":"2023","journal-title":"Neuroscience"},{"key":"10.1016\/j.diabet.2025.101612_bib0143","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/acer.15049","article-title":"The vicious cycle between (neuro)inflammation and alcohol use disorder: an opportunity to develop new medications?","volume":"47","author":"Leko","year":"2023","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.diabet.2025.101612_bib0144","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11695-017-2913-1","article-title":"A meta-analysis of GLP-1 after Roux-en-Y gastric bypass: impact of surgical technique and measurement strategy","volume":"28","author":"Jirapinyo","year":"2018","journal-title":"Obes Surg"},{"key":"10.1016\/j.diabet.2025.101612_bib0145","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/5908656","article-title":"Increasing GLP-1 circulating levels by bariatric surgery or by GLP-1 receptor agonists therapy: why are the clinical consequences so different?","volume":"2016","author":"Amouyal","year":"2016","journal-title":"J Diabetes Res"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T04:42:01Z","timestamp":1740717721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":145,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S1262363625000084"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101612","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Weight loss therapy and addiction: Increased risk after bariatric surgery but reduced risk with GLP-1 receptor agonists","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101612","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101612"}}